Last reviewed · How we verify
Tesomet "High dose" in fed condition
Tesomet is a combination of tesofensine (a monoamine reuptake inhibitor) and metformin that promotes weight loss by increasing satiety and energy expenditure while improving metabolic control.
Tesomet is a combination of tesofensine (a monoamine reuptake inhibitor) and metformin that promotes weight loss by increasing satiety and energy expenditure while improving metabolic control. Used for Chronic weight management in obese or overweight adults.
At a glance
| Generic name | Tesomet "High dose" in fed condition |
|---|---|
| Also known as | Tesofensine, Metoprolol |
| Sponsor | Saniona |
| Drug class | Monoamine reuptake inhibitor + biguanide combination |
| Target | Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT); metformin targets mitochondrial glycerophosphate dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Obesity / Diabetes |
| Phase | FDA-approved |
Mechanism of action
Tesofensine inhibits the reuptake of serotonin, norepinephrine, and dopamine in the central nervous system, leading to increased appetite suppression and thermogenesis. Metformin improves insulin sensitivity and glucose metabolism. The combination is designed to address both weight loss and glycemic control in obese and overweight patients.
Approved indications
- Chronic weight management in obese or overweight adults
Common side effects
- Nausea
- Headache
- Dizziness
- Insomnia
- Tachycardia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tesomet "High dose" in fed condition CI brief — competitive landscape report
- Tesomet "High dose" in fed condition updates RSS · CI watch RSS
- Saniona portfolio CI